nickel acetate has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 1 studies
*Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fan, L; Hu, A; Li, F; Liang, J; Liu, C; Mu, CF; Xiong, Y | 1 |
1 other study(ies) available for nickel acetate and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
Dual oligopeptides modification mediates arsenic trioxide containing nanoparticles to eliminate primitive chronic myeloid leukemia cells inside bone marrow niches.
Topics: Acetates; Animals; Arsenic Trioxide; Bone Marrow; Cell Proliferation; Cells, Cultured; Drug Delivery Systems; Female; Human Umbilical Vein Endothelial Cells; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Nanoparticles; Neoplastic Stem Cells; Oligopeptides; Organometallic Compounds; Polymers; Tumor Stem Cell Assay | 2020 |